GlassScriptPhysician profile
Jianxin Ma
NPI 1700910643
$14,479.39
in general payments reported to CMS, 2019-2025
61 companies · $1,337 in 2025
The $1,337 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $645 · 2020: $2,128 · 2021: $2,386 · 2022: $2,710 · 2023: $2,674 · 2024: $2,599 · 2025: $1,337.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,611.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,610.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,319.16 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $1,114.16 | 2019-2025 | Austedo Xr, Austedo, Ajovy |
| Ucb, INC. | $805.47 | 2019-2025 | Briviact, Rystiggo, Nayzilam |
| Lilly USA, LLC | $767.18 | 2020-2025 | Kisunla, Emgality, Reyvow |
| Lundbeck LLC | $766.28 | 2022-2025 | Vyepti, Rexulti |
| Sk Life Science, INC. | $766.12 | 2020-2025 | Xcopri |
| Pfizer INC. | $653.78 | 2023-2025 | |
| Amgen INC. | $623.02 | 2020-2025 | Uplizna, Repatha, Aimovig |
| Biogen, INC. | $610.64 | 2019-2024 | Tysabri, Vumerity |
| Celgene Corporation | $550.15 | 2021-2025 | Zeposia |
| Novartis Pharmaceuticals Corporation | $489.01 | 2019-2025 | |
| Amneal Pharmaceuticals LLC | $455.89 | 2019-2025 | Rytary, Crexont |
| Emd Serono, INC. | $434.00 | 2019-2023 | Mavenclad |
| Genentech USA, INC. | $422.97 | 2019-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Argenx US, INC. | $400.76 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jianxin Ma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.